1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025

 
• By Andrew McConaghie

The company is moving quickly to bring its antibody oligonucleotide conjugates to patients in three separate muscular dystrophy diseases, causing unease for its rivals.

(Shutterstock)

Avidity Biosciences could be about to transform treatment of three muscular dystrophy diseases with first-in-class RNA-based therapies, the most advanced being on track for filing by the end of 2025.

The San Diego, CA-based firm is developing a new hybrid drug class called antibody oligonucleotide conjugates (AOCs), which use monoclonal antibodies to transport oligonucleotide therapies into muscle and cardiac tissue,

Early readouts from its candidates last year made the company one of best-performing mid-cap biopharma stocks in 2024, and

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Therapy Areas

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.